Roche signed a deal to acquire Boston-based AI pathology company PathAI for $750 million upfront, with an additional $300 million available if certain milestones are achieved. The acquisition is expected to close in the second half of 2026 and aims to accelerate Roche's use of artificial intelligence to help pathologists diagnose diseases.
Roche acquisition deal
- ▪The Roche acquisition of PathAI could generate an additional $300 million for PathAI if certain milestones are achieved
- ▪The Roche acquisition of PathAI is expected to close in the second half of 2026
- ▪Roche signed a deal to pay $750 million upfront to acquire PathAI
PathAI company background
- ▪Andy Beck is the chief executive and cofounder of PathAI
AI-powered pathology technology
- ▪Roche's global infrastructure and expertise will bring PathAI's digital diagnostics technology to patients worldwide
- ▪Roche's acquisition of PathAI aims to speed up Roche's use of artificial intelligence to help pathologists diagnose disease
- ▪PathAI's mission is to improve patient outcomes through AI-powered pathology
Story comments
Loading comments…